The U.S. FDA has approved Beovu® (brolucizumab-dbll) 6mg, made by Novartis, to treat diabetic macular edema (DME). DME is a leading cause of blindness in adults in developed countries.

• DME is the leading cause of new blindness in adults in the United States. It affects approximately 12% of individuals who have type 1 diabetes and 28% of those who have type 2 diabetes.
• This is Beovu’s second FDA-approved indication. The drug was first approved in 2019 to treat neovascular (wet) age-related macular degeneration.
• Recommended dosing under the new indication is 6mg once every six weeks for the first five doses, then 6mg once every 8-12 weeks for subsequent doses. Beovu is injected into the vitreous cavity at the back of the eye by a qualified healthcare professional.